Chong Qiu | Nanomedicine | Young Scientist Award

Assoc Prof Dr. Chong Qiu | Artificial Intelligence | Young Scientist Award

Associate Professor at China Academy of Chinese Medical Sciences, China

Dr. Chong Qiu is an Associate Professor at the Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. He earned his PhD from Peking University, specializing in nanocarriers for drug delivery, siRNA, and peptide therapeutics. Dr. Qiuā€™s research focuses on innovative nanoparticle-based drug delivery systems, with applications in cancer treatment, pulmonary fibrosis, and targeted gene therapies. His work is widely recognized, with numerous high-impact publications in prestigious journals like Nature Communications and Journal of Nanobiotechnology. He is also a board member of several scientific journals and a leading expert in his field.

Publication profile

Education:

  • PhD in Pharmaceutical Science, Peking University, 2019
  • Bachelorā€™s degree, Peking University, 2014

Research Interests:

  • Nanocarriers for siRNA delivery
  • Nano-carriers for oral protein and peptide
  • Targeted nanoparticulate drug delivery

Professional Roles:

  • Young Scientist Board Member for Asian Journal of Pharmaceutical Sciences, iMeta, and Traditional Medicine Research and Exploration

Publication

  1. Photoaffinity probe-based antimalarial target identification of artemisinin in the intraerythrocytic developmental cycle of Plasmodium falciparum
    Journal: iMeta
    Year: 2024
    DOI: 10.1002/IMT2.176
    Contributors: Gao, Peng; Wang, Jianyou; Qiu, Chong; Zhang, Huimin; Wang, Chen; Zhang, Ying; Sun, Peng; Chen, Honglin; Wong, Yin Kwan; Chen, Jiayun et al.

 

  1. Enhanced tumor penetration across the blood-brain barrier: endoplasmic reticulum membrane hybrid siRNA nanoplexes
    Journal: Materials Today Nano
    Year: 2024
    DOI: 10.1016/j.mtnano.2023.100442
    Contributors: Chong Qiu; Shun Tao Liang; Qing Chao Tu; Chen Pan; Jia Yin Han; Bo Wu; Qiu Yan Guo; Yu Qian Lu; Jun Zhe Zhang; Yu Qing Meng et al.

 

  1. Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery
    Journal: Research
    Year: 2023
    DOI: 10.34133/RESEARCH.0148
    Contributors: Qiu, Chong; Xia, Fei; Zhang, Junzhe; Shi, Qiaoli; Meng, Yuqing; Wang, Chen; Pang, Huanhuan; Gu, Liwei; Xu, Chengchao; Guo, Qiuyan et al.

 

  1. Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy
    Journal: International Journal of Biological Sciences
    Year: 2023
    DOI: 10.7150/ijbs.79328
    Contributors: Chong Qiu; Yanyan Wu; Qiaoli Shi; Qiuyan Guo; Junzhe Zhang; Yuqing Meng; Chen Wang; Fei Xia; Jigang Wang; Chengchao Xu

 

  1. Anemoside B4 alleviates neuropathic pain through inhibiting inflammation
    Source: ResearchSquare
    Year: 2022
    DOI: 10.21203/rs.3.rs-1821028
    Contributors: Zhao, M.; Li, H.; Yang, T.; Qiu, C.; Lu, T.; Wang, Q.; Guo, Q.; Wang, J.

 

  1. Preparation and application of calcium phosphate nanocarriers in drug delivery
    Journal: Materials Today Bio
    Year: 2022
    DOI: 10.1016/j.mtbio.2022.100501
    Contributors: Chong Qiu; Yanyan Wu; Qiuyan Guo; Qiaoli Shi; Junzhe Zhang; Yuqing Meng; Fei Xia; Jigang Wang

 

šŸ† Conclusion

Dr. Chong Qiu is highly suitable for a Young Scientist Award. His innovative research, strong publication record, and leadership roles in the field of nanotechnology-based drug delivery make him a compelling candidate. With some strategic improvements in expanding research impact and fostering international collaborations, he has the potential to significantly advance the scientific community’s understanding of targeted therapeutics.

 

Antonios Kousaxidis | Medicinal Chemistry | Best Researcher Award

Ā Mr. Antonios Kousaxidis | Medicinal Chemistry |Best Researcher Award

Ā Mr at School of Pharmacy, Aristotle University of Thessaloniki, Greece

A seasoned educator and researcher with extensive experience in physics, holding positions from Assistant to Associate Professor at IAU, Urmia, and Urmia University of Technology. Specialized in teaching a range of undergraduate to Ph.D. courses including Quantum Mechanics, Laser Physics, and Nonlinear Dynamical Systems. Proficient in Maple and Matlab programming with a strong background in finite element method analysis. Led impactful research projects in chaotic systems, cancer treatment, and national security, earning multiple awards including the Kharazmi Scientific Festival Second Prize. A recognized leader in academia with a commitment to advancing scientific knowledge and education.

Profile

  1. Scopus

šŸŽ“ Education:

Masterā€™s Degree in Medicinal Chemistry: (9.85/10) from Departments of Chemistry, Medicine, Biological Applications and Technology, University of Ioannina, 45110, Ioannina, Greece.Ā Bachelor’s Degree in Chemistry: (7.76/10) from Department of Chemistry, School of Sciences, University of Ioannina, 45110, Ioannina, Greece.

Personal Skills:

Synthetic Organic Chemistry and Biochemistry: Training in synthetic organic chemistry and biochemistry applied to drug design, with experience in several areas of synthetic methodology using retrosynthetic approaches. Metal-Based Coupling Reactions: Excellent knowledge and practice of metal-based coupling reactions in modern organic chemistry. Synthetic Routes Optimization: Training in synthetic routes optimization using one-pot reactions during masterā€™s thesis. Analytical Methods: Proficient in NMR, IR, UV, and mass spectrometry for identifying organic compounds. Small Molecule Synthesis: Synthesis of small molecule organic compounds and isolation by recrystallization. Purification and Separation: Excellent knowledge and practice in chromatographic methods like column, preparative, and thin-layer chromatography for purifying and separating organic compounds. Biochemical Protocols: Good practice in using biochemical protocols for enzyme kinetics experiments. Drug Discovery Programs: Extensive experience in drug discovery programs, structure-based drug design, molecular docking, and SAR estimation models using in silico methods (Discovery Studio, Chimera, LigandScout, PyMOL, OpenBabel, ADMET). Scientific Manuscripts: Proficient in writing and preparing scientific manuscripts.

šŸ’» Software Skills:

Office Suite (ECDL degree) – Word processing, spreadsheets, presentations, etc. Calculative and predictive programs like MestReNova, Topspin DataAnalysis, ChemDraw Ultra, MedChem Designer, and BioLoom.

Research Focus:

A. Kousaxidis primarily focuses on the design and synthesis of novel compounds with therapeutic potential, particularly targeting enzymes such as aldose reductase (ALR2) and protein tyrosine phosphatase 1B (PTP1B). The research also encompasses antimicrobial agents, lipoxygenase inhibitors, and therapeutic strategies for conditions like diabetes mellitus and sepsis.

Publications Top Notes šŸ“

  • A Molecular Hybridization Approach for the Design of Selective Aldose Reductase (ALR2) Inhibitors and Exploration of Their Activities Against Protein Tyrosine Phosphatase 1B (PTP1B)
    • Authors: Kousaxidis, A., Petrou, A., Rouvim, P., Nicolaou, I., Geronikaki, A.
    • Journal: Journal of Molecular Structure
    • Year: 2023
    • Volume: 1271
    • Article Number: 134116
    • Citations: 3
    • Summary: This study presents a hybridization approach to develop selective ALR2 inhibitors and investigates their potential activities against PTP1B, highlighting their dual therapeutic potential.

 

  • Design, Synthesis, and Pharmacological Evaluation of Indazole Carboxamides of N-Substituted Pyrrole Derivatives as Soybean Lipoxygenase Inhibitors
    • Authors: Lavrentaki, V., Kousaxidis, A., Theodosis-Nobelos, P., Koutsopoulos, K., Nicolaou, I.
    • Journal: Molecular Diversity
    • Year: 2023
    • Citations: 2
    • Summary: This paper discusses the synthesis and evaluation of novel indazole carboxamides, demonstrating significant inhibitory activity against soybean lipoxygenase.

 

  • N-Derivatives of (Z)-Methyl 3-(4-Oxo-2-thioxothiazolidin-5-ylidene)methyl)-1H-indole-2-carboxylates as Antimicrobial Agentsā€”In Silico and In Vitro Evaluation
    • Authors: Petrou, A., Geronikaki, A., Kartsev, V., Nicolaou, I., Vizirianakis, I.S.
    • Journal: Pharmaceuticals
    • Year: 2023
    • Volume: 16
    • Issue: 1
    • Article Number: 131
    • Citations: 4
    • Summary: This open-access article evaluates the antimicrobial activity of new N-derivatives, supported by both in silico and in vitro methods.

 

  • Non-acidic Bifunctional Benzothiazole-Based Thiazolidinones with Antimicrobial and Aldose Reductase Inhibitory Activity as a Promising Therapeutic Strategy for Sepsis
    • Authors: Kousaxidis, A., Kovacikova, L., Nicolaou, I., Stefek, M., Geronikaki, A.
    • Journal: Medicinal Chemistry Research
    • Year: 2021
    • Volume: 30
    • Issue: 10
    • Pages: 1837-1848
    • Citations: 13
    • Summary: This research explores benzothiazole-based thiazolidinones with dual activity, suggesting a promising approach for treating sepsis.

 

  • Aldose Reductase and Protein Tyrosine Phosphatase 1B Inhibitors as a Promising Therapeutic Approach for Diabetes Mellitus
    • Authors: Kousaxidis, A., Petrou, A., Lavrentaki, V., Nicolaou, I., Geronikaki, A.
    • Journal: European Journal of Medicinal Chemistry
    • Year: 2020
    • Volume: 207
    • Article Number: 112742
    • Citations: 39
    • Summary: This review highlights the potential of targeting ALR2 and PTP1B as a therapeutic strategy for diabetes, emphasizing recent advances and future perspectives.